Technology | Contrast Media | February 02, 2017

Lantheus Medical Imaging Announces FDA Approval of Definity Label Update

Label revision removes cardiac shunt contraindication

Lantheus Medical Imaging, Definity, FDA approval, label update, echocardiography, cardiac shunt contraindication

February 2, 2017 — Lantheus Medical Imaging Inc. announced U.S. Food and Drug Administration (FDA) approval of a label update for Definity Vial for (Perflutren Lipid Microsphere) Injectable Suspension. The update removes the contraindication statement related to use in patients with a known or suspected cardiac shunt from the U.S. Prescribing Information.

Definity is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

A cardiac shunt is a pattern of blood flow in the heart that deviates from the normal path of the circulatory system, which may present in 10 to 35 percent of patients. These patients were previously excluded from receiving a valuable echo contrast study of the left ventricle. The FDA’s decision to remove the contraindication concerning known or suspected cardiac shunts was based on Lantheus’ submission referencing several publications and data supporting the safety of echocardiography contrast products in patients with cardiac shunts. Information concerning administration in patients with a cardiac shunt appears in the Warnings section of the Definity Prescribing Information.

Neil Weissman, M.D., president of MedStar Health Research Institute (Washington, D.C.), professor of medicine at Georgetown University and past president of the American Society of Echocardiography commented, “The echocardiography medical and scientific community has long demonstrated the safety of echocardiographic contrast agents through published clinical studies which has supported the removal of the contraindication for Definity in patients with cardiac shunts. This is particularly noteworthy as Definity is the most widely used echocardiography agent in the U.S. with published data supporting its safety profile across multiple care settings and across gender and race in adults, including those age 65 and older.”

Weissman continued, “This is an important step toward broader acceptance and appropriate use of echo contrast agents, which can safely and cost effectively provide critical information to help clinicians accurately diagnose and manage patients to achieve better outcomes.”

Up to 20 percent of all resting echocardiography studies and up to 30 percent of those conducted in critical care patients can result in suboptimal echocardiograms. A suboptimal image is one in which two or more contiguous left ventricular segments in any of the three apical views cannot be visualized. The use of contrast in suboptimal echocardiograms may help with clinical evaluation of the patient.

For more information: www.lantheus.com

Related Content

Fujifilm Exhibits Enterprise Imaging Solutions and Artificial Intelligence Initiative at HIMSS 2019
News | Enterprise Imaging | February 15, 2019
Fujifilm Medical Systems U.S.A. Inc. and Fujifilm SonoSite Inc. showcased their enterprise imaging and informatics...
Philips Launches Latest Iteration of IntelliSpace Cardiovascular at HIMSS 2019
Technology | Cardiac PACS | February 13, 2019
Philips announced the launch of IntelliSpace Cardiovascular 4.1, its next-generation cardiovascular image and...
Micro-Ultrasound and Artificial Intelligence Combining to Detect Prostate Cancer
News | Prostate Cancer | February 12, 2019
Cambridge Consultants has partnered with Exact Imaging, makers of the ExactVu micro-ultrasound platform, as the two...
An example of Philips' TrueVue technology, which offers photo-realistic rendering and the ability to change the location of the lighting source on 3-D ultrasound images. In this example of two Amplazer transcatheter septal occluder devices in the heart, the operator demonstrating the product was able to push the lighting source behind the devices into the other chamber of the heart. This illuminated a hole that was still present that the occluders did not seal.

An example of Philips' TrueVue technology, which offers photo-realistic rendering and the ability to change the location of the lighting source on 3-D ultrasound images. In this example of two Amplazer transcatheter septal occluder devices in the heart, the operator demonstrating the product was able to push the lighting source behind the devices into the other chamber of the heart. This illuminated a hole that was still present that the occluders did not seal. 

Feature | Ultrasound Imaging | February 07, 2019 | Dave Fornell, Editor
Here is a list of six key trends in ul...
Epiq Elite for Obstetrics and Gynecology delivers high image quality and lifelike 3-D scans

The Epiq Elite for Obstetrics & Gynecology. Image courtesy of Philips Healthcare.

Technology | Ultrasound Imaging | February 07, 2019
Philips announced the launch of the Epiq Elite ultrasound system, a new premium ultrasound that combines the latest...
ASE Releases Guidelines for Transesophageal Echo in Congenital Heart Disease
News | Ultrasound Transesophageal echo (TEE) | February 05, 2019
February 5, 2019 – The American Society of Echocardiography (ASE) released a new document that provides a comprehensi
Konica Minolta Releases Sonimage HS1 Ultrasound Software Upgrade
News | Ultrasound Imaging | January 31, 2019
Konica Minolta Healthcare Americas Inc. released a new software upgrade for the Sonimage HS1 Ultrasound System that...
QTbreasthealth Opens New Breast Ultrasound Imaging Center in Grand Rapids
News | Ultrasound Women's Health | January 30, 2019
January 30, 2019 — QTbreasthealth launched a center in Grand Rapids, Mich., featuring its quantitative transmission
Sponsored Content | Case Study | Contrast Media | January 30, 2019
The medical imaging market relies heavily on contrast media, injected into patients to increase the contrast of bodil
Sponsored Content | Videos | Contrast Media | January 22, 2019
ITN Contributing Editor Greg Freiherr speaks with Guerb